SINTEF Materials and Chemistry Biotechnology and Nanomedicine
RESEARCH, TECHNOLOGY AND INNOVATION
Biotechnology and nanomedicine are key enabling technologies for various sectors of society and multiple industries. The technology is used in development of pharmaceuticals, vaccines, biomaterials, enzymes, food, feed, chemicals and energy. SINTEF Materials and Chemistry has a strong operation in the fields of microbial molecular biology, bioprocess- and medical technology, biopolymers/polymers, biopharmaceuticals and nanomedicine, and is operating a state-of-the-art research infrastructure including advanced mass spectrometry.
High throughput screening facility, Trondheim
The robotic screening facility at SINTEF are optimized for high throughput analytical and cultivation work and enables us to process of thousands of samples or cultures per day.
Molecular biology laboratory
We have state of the art equipment for molecular biology, including an Illumina MiSeq sequencer, droplet digital PCR (ddPCR), Agilent Bioanalyzer, CHEF Mapper XA pulse field gel electrophoresis system and a Bluepippin cassette-based gel electrophoresis system for DNA and protein separation, in addition to ÄKTA FPLC equipment for protein purification. Our co-workers have several years of experience and master most topics and protocols related to genetic modification of bacteria.
Fermentation laboratory at SINTEF
SINTEF has a nationally leading research laboratory for development of microbial and cell based production processes. The laboratory has robotic equipment for miniaturized cultivation, large capacity incubators for shake flasks, laboratory fermentors (1-3 L) equipped for extensive process control and monitoring, and a pilot plant with two fermenters (50 and 300 L) for scale-up studies and small productions.
DAFIA - Biomacromolecules from municipal solid bio-waste fractions and fish waste for high added value applications
The main objective of DAFIA is to exploit municipal solid wastes (MSW) and marine rest raw materials (MRRM) as feedstocks for higher value products. Municipal solids wastes represents more than 500 kg/capita (EU-27 average) and 300 million tonnes overall every year in the EU-32. Currently, approximately 50% of this volume is landfilled, while the rest is incinerated for energy production.
BubbleCAN – Microbubbles for Ultrasound-Mediated Cancer Treatment
BubbleCAN addresses the optimization of a product for the delivery of very high local concentrations of drugs to tumors using non-invasive focused ultrasound. The product is based on SINTEF owned technology platforms.
Smartfish NutriDrug: Efficient oral drug delivery system for the treatment of cancer and infectious diseases
New solutions for orally administrated drugs are in demand by users, society and the pharmaceutical industry. The overall goal of NutriDrug is to develop a novel and efficient oral drug delivery system for the treatment of cancer and infectious diseases.
New allergy test promises safer antibiotic use
Allergies to antibiotics are the commonest form of medication allergies and, in the worst cases, can result in anaphylaxis and death. SINTEF is participating in the development of a new allergy test that will make it easier to provide patients with safe and correct treatments.
Commercialising gas bubbles for cancer drug delivery
Researchers are now working to design stable micro-bubbles which, combined with ultrasound, can deliver cancer drugs straight to the target tumour.